T. Papagiannakopoulos

Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growth

This study identifies a LKB1-LIF signaling axis in tumors that promotes immune evasion by reprogramming myeloid cells, and shows that inhibiting LIF signaling reduces tumor growth.

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

This study shows that DRP-104, a glutamine antagonist, suppresses KEAP1 mutant lung tumor growth and enhances response to checkpoint blockade by inhibiting glutamine metabolism and improving T cell function.

Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumors.

The paper shows that inhibiting HDACs selectively targets NRF2-activated lung adenocarcinoma by altering chromatin and metabolic pathways.

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

This study shows KEAP1 mutations in lung adenocarcinoma lead to immune evasion by reducing dendritic cell and T cell responses, contributing to immunotherapy resistance.